Login to Your Account



Biovitrum Lands Blockbuster With Amgen For Diabetes Drug

By Cormac Sheridan


Wednesday, September 10, 2003
Biovitrum AB, the Swedish drug development firm spun out of Pharmacia Corp., entered one of Europe's landmark biotechnology deals of 2003, a pact with Amgen Inc. to develop small-molecule, selective inhibitors of 11beta-hydroxysteroid dehydrogenase 1 for Type II diabetes and other metabolic diseases. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription